Resistant HypertensionMOMENTUMNCT06829537
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
An observational study of Resistant Hypertension and Hypercortisolism, run by Corcept Therapeutics at 50 sites in United States.
Trial summary
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Resistant Hypertension, Hypercortisolism
- How many people
- 1,143 participants
- Where
- 50 sitesUnited States
- Study dates
- 28 Mar 2025to 23 Jan 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Office-based care and university clinics in the United States.
Who may be able to join
- Each patient must meet all of the following criteria to be enrolled in the study:
- Signed and dated Institutional Review Board (IRB)-approved informed consent form (ICF) prior to any study-specific screening procedures.
- Male/female patients must be 18 years or older at the time of signing the informed consent.
- Meet either of the following criteria:
- Has rHTN, defined by the American Heart Association as BP above target (systolic ≥ 130 mmHg for purposes of this study) despite concurrent use of 3 or more antihypertensive medications from different classes at their maximally tolerated doses, and 1 of these agents is a diuretic.
- Or, has rHTN, defined by the American Heart Association as SBP at target or above target requiring concurrent use of 4 or more antihypertensive medications of different classes.
Who cannot join
- Patients who meet any of the following criteria will not be permitted entry to the study:
- White coat hypertension, ie, elevated BP in the office only, as determined by the Investigator.
- Non-adherence to BP medications, as determined by the Investigator.
- Systemic glucocorticoid medications exposure (excluding inhalers or topical) within 3 months of screening. For temporary exposures to oral glucocorticoids the Medical Monitor may be consulted to determine eligibility.
- Has an historical estimated glomerular filtration rate (eGFR) < 30.
- Has severe untreated sleep apnea as determined by the Investigator.
Show all 15Show fewer
- Has excessive alcohol consumption (eg, > 14 units/week for male, > 7 units/week for female) as determined by the Investigator.
- Has severe acute psychiatric, medical, or surgical illness, as determined by the Investigator.
- Is a woman who is pregnant or lactating. For women of childbearing potential, a urine pregnancy test must be negative before doing the DST. A woman of childbearing potential includes women < 50 years old, women whose surgical sterilization was performed < 6 months ago, and women who have had a menstrual period in the last 12 months.
- Is a woman who is on oral contraceptive pills (OCPs). Women on OCPs may be screened but must be willing and able to stop OCPs for at least 6 weeks prior to screening assessments. OCPs can be resumed immediately after the blood draw for the DST.
- Has history of congenital adrenal hyperplasia.
- Has had the diagnosis of Cushing syndrome and/or has used or plans to use any of the following treatments for Cushing syndrome:
- Mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, lanreotide, pasireotide, longacting octreotide or pasireotide.
- Is unable to take dexamethasone due to a history of hypersensitivity or severe reaction to dexamethasone.
- Is a staff member working directly on the study or is a family member of someone working directly on the study, including any of the Sponsor's employees, the Investigator or the site staff.
Trial locations and contacts
50 sites in 1 country.
50 sites in 1 country
United States50 sites
Site 070
Albany, New York, 12203
Site 009
Atlanta, Georgia, 30303
Site 456
Austin, Texas, 78759
Site 410
Baltimore, Maryland, 21239
Site 067
Boston, Massachusetts, 02115
Site 181
Chapel Hill, North Carolina, 27514
Site 168
Charleston, South Carolina, 29425
Site 552
Chicago, Illinois, 60607
Site 436
Cincinnati, Ohio, 45219
Site 551
Cleveland, Ohio, 44109
Site 042
Cleveland, Ohio, 44195
Site 195
Columbus, Ohio, 43201
Site 553
Cooper City, Florida, 33024
Site 046
Covington, Kentucky, 41011
Site 370
Dallas, Texas, 75230
Site 536
Durham, North Carolina, 27701
Site 444
Edgewater, Florida, 32132
Site 555
Greenville, North Carolina, 27834
Site 526
Houston, Texas, 77054
Site 378
Huntington Park, California, 90255
Site 406
La Jolla, California, 92037
Site 538
La Jolla, California, 92037
Site 371
Las Vegas, Nevada, 89148
Site 041
Los Angeles, California, 90048
Site 408
Lufkin, Texas, 75904
Site 528
Maitland, Florida, 32751
Site 061
Metairie, Louisiana, 70006
Site 554
Miami, Florida, 33126
Site 525
Miami, Florida, 33155
Site 527
Miami, Florida, 33173
Site 529
Mooresville, North Carolina, 28117
Site 540
Morrisville, North Carolina, 27560
Site 534
Mt. Pleasant, South Carolina, 29464
Site 377
New Orleans, Louisiana, 70112
Site 524
New York, New York, 10029
Site 535
Northridge, California, 91324
Site 394
Olney, Maryland, 20832
Site 537
Port Charlotte, Florida, 33952
Site 379
Redondo Beach, California, 90247
Site 541
Reno, Nevada, 89502
Site 440
Rockville, Maryland, 20854
Site 369
San Antonio, Texas, 78229
Site 542
Santa Maria, California, 93454
Site 387
Tarzana, California, 91356
Site 375
Torrance, California, 90502
Site 533
Torrance, California, 90505
Site 530
Troy, Michigan, 48085
Site 531
Weslaco, Texas, 78596
Site 059
Wilmington, North Carolina, 28401
Site 532
Winfield, Illinois, 60190
About this study
Official title: Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension in the United States of America (MOMENTUM)
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US).
Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. Non-fasting labs and a urine collection will also be done. A second visit will be a fasting blood draw at 8 AM after taking 1 mg of dexamethasone the night before at 11 PM. Cortisol level and study labs will also be collected.
After the lab results are obtained, a third visit will be scheduled only for patients with eHC and will include a non-fasting blood draw at 8 AM and scheduling of a non-contrast CT scan.
Read the detailed description
This is a non-interventional study enrolling approximately 1000 patients at approximately 45 sites in the (US) and will assess the prevalence of eHC in patients with rHTN.
For the purpose of this study, eHC is defined by post-dexamethasone suppression test (DST) cortisol > 1.8 μg/dL with serum dexamethasone levels ≥ 140 μg/dL in a population meeting the inclusion and exclusion criteria for this study.
rHTN is defined by the American Heart Association as 1) systolic blood pressure (SBP) above target (≥ 130 mmHg for purposes of this study) despite concurrent use of 3 or more antihypertensive medications from different classes including a diuretic at their maximally tolerated doses or 2) at target or above target SBP requiring concurrent use of 4 or more antihypertensive medications from different classes.
Each patient will have an initial visit for screening. After written informed consent and eligibility is confirmed including a urine pregnancy test (if applicable), blood pressure, weight, height and waist circumference will be checked, and medical history will be obtained. Non-fasting labs such as plasma renin activity, aldosterone, N-terminal-pro brain natriuretic peptide, complete blood count, high sensitivity C-reactive protein, hemoglobin A1c, and comprehensive metabolic panel will be collected. A urine test will also be performed for albumin to creatinine ratio.
A second visit will be at 8 AM (± 1 hour) the morning after taking 1 mg of dexamethasone at 11 PM the night before. The blood draw must be in the fasted state and will include cortisol level, lipid panel, adrenocorticotropic hormone (ACTH), and fasting glucose. Dexamethasone level will be checked automatically for any cortisol >1.8 μg/dL (eHC).
After the DST results are obtained, a third visit will be scheduled only for patients with eHC and will include a non-fasting 8 AM blood draw for ACTH and cortisol and scheduling of a non- contrast adrenal CT scan.
- Conditions
- Resistant Hypertension, Hypercortisolism
- Keywords
- Hypercortisolism, Resistant Hypertension
- Medical subject headings
- Cushing Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the prevalence of endogenous hypercortisolism in a population with resistant hypertension.
Prevalence of endogenous hypercortisolism in a population with resistant hypertension will be described as the percentage of patients with post-DST cortisol > 1.8 μg/dL with dexamethasone level ≥ 140 ng/dL among all patients enrolled.
Measured: From enrollment to the end of the study which is approximately 4 weeks.
Secondary outcomes (3)
Assess clinical characteristics that increase the likelihood of a patient having endogenous hypercortisolism of those with and without abnormal adrenal imaging.
- Clinical characteristics collected as medical history will be coded and presented by system organ class (SOC) and preferred term (PT).
Measured: From enrollment to the end of the study which is approximately 4 weeks.
Assess laboratory characteristics that increase the likelihood of a patient having endogenous hypercortisolism of those with and without abnormal adrenal imaging.
Laboratory characteristics will be summarized using descriptive statistics (mean, standard deviation, minimum, maximum, and 95% CI for mean). All will be assessed to identify associations with endogenous hypercortisolism diagnosis.
Measured: From enrollment to the end of the study which is approximately 4 weeks.
Assess the likelihood of a patient having endogenous hypercortisolism of those with and without abnormal adrenal imaging.
- In patients with endogenous hypercortisolism and resistant hypertension, the percentage of patients with and without abnormal adrenal imaging based on non-contrast CT scan.
Measured: From enrollment to the end of the study which is approximately 4 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2025
- Study start28 Mar 2025
- Primary completion8 Dec 2025
- Study completion23 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Resistant HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,143 participants (actual)
Sponsor and investigators
- Lead sponsor
- Corcept Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06829537
- Sponsor's protocol ID
- Study 311
- Acronym
- MOMENTUM
- Status last verified
- Feb 2026
- First submitted
- 30 Jan 2025
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Upon study completion, results will be presented at relevant scientific congresses and published in a peer-reviewed journal.
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension in the United States of America (MOMENTUM)
- ClinicalTrials.gov ID
- NCT06829537
- Acronym / sponsor ID
- MOMENTUM / Study 311
- Conditions
- Resistant Hypertension, Hypercortisolism
- Keywords
- Hypercortisolism, Resistant Hypertension
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,143 participants (actual)
- Lead sponsor
- Corcept TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 28 Mar 2025 (actual)
- Primary completion
- 8 Dec 2025 (actual)
- Study completion
- 23 Jan 2026 (actual)
- First posted
- 17 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US).
Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. Non-fasting labs and a urine collection will also be done. A second visit will be a fasting blood draw at 8 AM after taking 1 mg of dexamethasone the night before at 11 PM. Cortisol level and study labs will also be collected.
After the lab results are obtained, a third visit will be scheduled only for patients with eHC and will include a non-fasting blood draw at 8 AM and scheduling of a non-contrast CT scan.
Detailed description
This is a non-interventional study enrolling approximately 1000 patients at approximately 45 sites in the (US) and will assess the prevalence of eHC in patients with rHTN.
For the purpose of this study, eHC is defined by post-dexamethasone suppression test (DST) cortisol > 1.8 μg/dL with serum dexamethasone levels ≥ 140 μg/dL in a population meeting the inclusion and exclusion criteria for this study.
rHTN is defined by the American Heart Association as 1) systolic blood pressure (SBP) above target (≥ 130 mmHg for purposes of this study) despite concurrent use of 3 or more antihypertensive medications from different classes including a diuretic at their maximally tolerated doses or 2) at target or above target SBP requiring concurrent use of 4 or more antihypertensive medications from different classes.
Each patient will have an initial visit for screening. After written informed consent and eligibility is confirmed including a urine pregnancy test (if applicable), blood pressure, weight, height and waist circumference will be checked, and medical history will be obtained. Non-fasting labs such as plasma renin activity, aldosterone, N-terminal-pro brain natriuretic peptide, complete blood count, high sensitivity C-reactive protein, hemoglobin A1c, and comprehensive metabolic panel will be collected. A urine test will also be performed for albumin to creatinine ratio.
A second visit will be at 8 AM (± 1 hour) the morning after taking 1 mg of dexamethasone at 11 PM the night before. The blood draw must be in the fasted state and will include cortisol level, lipid panel, adrenocorticotropic hormone (ACTH), and fasting glucose. Dexamethasone level will be checked automatically for any cortisol >1.8 μg/dL (eHC).
After the DST results are obtained, a third visit will be scheduled only for patients with eHC and will include a non-fasting 8 AM blood draw for ACTH and cortisol and scheduling of a non- contrast adrenal CT scan.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Office-based care and university clinics in the United States.
Key inclusion criteria (6 listed)
- Each patient must meet all of the following criteria to be enrolled in the study:
- Signed and dated Institutional Review Board (IRB)-approved informed consent form (ICF) prior to any study-specific screening procedures.
- Male/female patients must be 18 years or older at the time of signing the informed consent.
- Meet either of the following criteria:
- Has rHTN, defined by the American Heart Association as BP above target (systolic ≥ 130 mmHg for purposes of this study) despite concurrent use of 3 or more antihypertensive medications from different classes at their maximally tolerated doses, and 1 of these agents is a diuretic.
Key exclusion criteria (15 listed)
- Patients who meet any of the following criteria will not be permitted entry to the study:
- White coat hypertension, ie, elevated BP in the office only, as determined by the Investigator.
- Non-adherence to BP medications, as determined by the Investigator.
- Systemic glucocorticoid medications exposure (excluding inhalers or topical) within 3 months of screening. For temporary exposures to oral glucocorticoids the Medical Monitor may be consulted to determine eligibility.
- Has an historical estimated glomerular filtration rate (eGFR) < 30.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To assess the prevalence of endogenous hypercortisolism in a population with resistant hypertension.
Time frame: From enrollment to the end of the study which is approximately 4 weeks.
Prevalence of endogenous hypercortisolism in a population with resistant hypertension will be described as the percentage of patients with post-DST cortisol > 1.8 μg/dL with dexamethasone level ≥ 140 ng/dL among all patients enrolled.
3 secondary outcomes
Assess clinical characteristics that increase the likelihood of a patient having endogenous hypercortisolism of those with and without abnormal adrenal imaging.
Time frame: From enrollment to the end of the study which is approximately 4 weeks.
Assess laboratory characteristics that increase the likelihood of a patient having endogenous hypercortisolism of those with and without abnormal adrenal imaging.
Time frame: From enrollment to the end of the study which is approximately 4 weeks.
Assess the likelihood of a patient having endogenous hypercortisolism of those with and without abnormal adrenal imaging.
Time frame: From enrollment to the end of the study which is approximately 4 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Individual participant dataSharing planned: Yes. Upon study completion, results will be presented at relevant scientific congresses and published in a peer-reviewed journal.
Related trials for Resistant Hypertension
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not yet recruitingPhase 2
A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patients
Uncontrolled Hypertension, Resistant Hypertension
Not yet recruitingObservational study
Common Carotid Artery-Renal Artery-Femoral Artery Survey for Hypertension
Hypertension, Hypertension (HTN)
Active, not recruiting
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Primary Aldosteronism, Resistant Hypertension
Recruiting
Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Atherosclerosis Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
50 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Resistant Hypertension and Hypercortisolism, run by Corcept Therapeutics at 50 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 50 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the prevalence of endogenous hypercortisolism in a population with resistant hypertension. (time frame: From enrollment to the end of the study which is approximately 4 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.